Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival by Eliza W. Beal et al.
June 2016 | Volume 6 | Article 1431
Original research
published: 13 June 2016
doi: 10.3389/fonc.2016.00143
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Nikolaos Arkadopoulos, 
Athens University School of Medicine, 
Greece
Reviewed by: 
Kun-Ming Chan, 
Chang Gung Memorial Hospital at 
Linkou, Taiwan  
Evangelos P. Misiakos, 
National and Kapodistrian University 
of Athens, Greece
*Correspondence:
Carl R. Schmidt  
carl.schmidt@osumc.edu
Specialty section: 
This article was submitted 
to Surgical Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 05 April 2016
Accepted: 26 May 2016
Published: 13 June 2016
Citation: 
Beal EW, Dittmar KM, Hanje AJ, 
Michaels AJ, Conteh L, Davidson G, 
Black SM, Bloomston PM, Dillhoff ME 
and Schmidt CR (2016) Pretransplant 
Locoregional Therapy for 
Hepatocellular Carcinoma: 
Evaluation of Explant Pathology 
and Overall Survival. 
Front. Oncol. 6:143. 
doi: 10.3389/fonc.2016.00143
Pretransplant locoregional Therapy 
for hepatocellular carcinoma: 
evaluation of explant Pathology and 
Overall survival
Eliza W. Beal1, Kristin M. Dittmar2, A. James Hanje3, Anthony J. Michaels3,  
Lanla Conteh3, Gail Davidson1, Sylvester M. Black1, P. Mark Bloomston1,  
Mary E. Dillhoff1 and Carl R. Schmidt1*
1 Department of Surgery, The Ohio State University Wexner Medical Center, James Cancer Hospital, Columbus, OH, USA, 
2 Department of Radiology, The Ohio State University Wexner Medical Center, James Cancer Hospital, Columbus, OH, USA, 
3 Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The Ohio State University Wexner 
Medical Center, Columbus, OH, USA
Background and objectives: Liver transplant is an important treatment option for 
patients with hepatocellular carcinoma (HCC) within Milan criteria. We sought to deter-
mine the rate of complete tumor necrosis after bridging therapy.
Methods: The medical records of all 178 patients undergoing liver transplantation 
between January 1, 2008 and July 31, 2015 were reviewed. Response to therapy by 
imaging was based on mRECIST criteria (1).
results: Sixty-three (35%) patients had HCC. Forty-three (68%) were treated with at 
least one bridging therapy and 14 (22%) were diagnosed incidentally. Eighteen (42%) 
underwent TACE and 25 (58%) underwent ablation. Twenty (80%) patients who under-
went ablation and nine (60%) who underwent TACE had complete response based 
on imaging. Viable tumor was identified in explant pathology in 32 patients (74%). The 
presence or absence of viable tumor was not associated with overall survival.
conclusion: Rates of viable tumor based on pathologic analysis in the hepatic explant 
were high after bridging therapy, but not associated with worse outcome. We conclude 
that serial bridging to achieve complete pathologic tumor response is not needed prior to 
transplant for HCC, and presence of complete response by imaging is adequate. Further 
studies are needed to determine if cancer cells that appear viable are alive.
Keywords: liver transplantation, carcinoma, hepatocellular, chemoembolization, therapeutic, radiofrequency 
ablation, microwave ablation, locoregional bridging therapy
inTrODUcTiOn
Hepatocellular carcinoma (HCC) is one of the few cancers with increasing incidence in the United 
States over the past two decades (2–4). Orthotopic liver transplant is widely accepted as a potentially 
curative treatment option for patients with early stage cancer defined by the Milan criteria (5–8). One 
limitation of this therapy is the growing incidence of waitlist dropouts due to increasing time on the 
list related to limited organ availability (9). In a recent consensus statement published in the Journal 
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of the National Comprehensive Cancer Network (JNCCN), it is 
recommended that patients with HCC be considered for bridg-
ing therapy (10) if they are expected to wait more than 6 months 
for transplantation in order to reduce dropouts from the waitlist 
secondary to tumor progression (11).
The most common bridging therapy options we use are 
transarterial chemoembolization (TACE) and percutaneous or 
laparoscopic ablation (11). Reported rates of complete tumor 
necrosis, or complete pathologic response, vary based on treat-
ment modality with response rates between 0 (12) and 57% (13) 
reported for TACE and 8.3 (12) and 74% (14) reported for radi-
ofrequency ablation. The primary objective of this study was to 
determine the rate of complete tumor necrosis after locoregional 
bridging therapy for HCC prior to liver transplantation, as deter-
mined by explant histopathology.
MaTerials anD MeThODs
After Institutional Review Board approval, the records of all adult 
patients who underwent liver transplantation between January 1, 
2008 and July 31, 2015 were reviewed using the electronic medical 
record and a prospectively maintained transplantation database. 
Demographic variables were collected, including type of trans-
plant, age, gender, calculated Model for End-stage Liver Disease 
(MELD) score, body mass index (BMI), etiology of  disease, 
and medical comorbidities. MELD score was calculated  using 
the  following formula: 10 × {[0.957 × ln(creatinine)] + [0.378 × 
ln(bilirubin)] + [1.12 × ln(INR)]} + 6.43, and exception points 
were not added. For any value <1.0, the value was set to 1.0 to 
avoid negative results. Any patient who had received dialysis 
twice in the previous 7 days had creatinine set to 4.0.
All patients in this cohort had a cancer therapy plan discussed 
at our center’s multidisciplinary liver tumor board. In general, 
ablation is considered for patients with three or less tumors 
with size <4 cm for any single tumor. Patients treated with at 
least one TACE prior to transplant were given either a triple-
drug cocktail (mitomycin C, cisplatin, and doxorubicin) with 
Lipiodol or DC beads®. TACE procedures were performed by 
our interventional radiology team using percutaneous femoral 
access and fluoroscopic guidance. Ablations were either per-
formed laparoscopically or percutaneously using CT-guidance. 
Laparoscopic ablations were performed by either of two surgi-
cal oncologists using a microwave source. CT-guided ablations 
were performed using radiofrequency ablation or microwave 
ablation and were performed by an interventional radiologist. 
The majority of patients were treated with appropriate antiviral 
therapy until the time of transplant.
All liver explants were examined by a pathologist special-
izing in hepatobiliary disease. Tumor viability was determined 
using standard hematoxylin and eosin staining. The presence 
and extent of tumor necrosis was characterized based on an 
estimated percent of necrosis. Cases where there was doubt about 
complete response were placed in the viable tumor category for 
the purpose of analysis. Statistical analysis was performed using 
Statistical Package for the Social Sciences version 22 (IBM, 
Armonk, NY, USA). Categorical variables were compared using 
Fisher’s exact test, and continuous variables were compared using 
the independent sample T-test. Survival curves were computed 
with the Kaplan–Meier method and differences in outcome 
determined by log-rank test.
resUlTs
There were 178-liver transplants completed during the study 
period, including 9-combined liver–kidney transplants (Table 1). 
The most common etiologies leading to transplantation were 
cirrhosis related to hepatitis C virus (HCV) or hepatitis B virus 
(HBV) infection, alcohol abuse, and non-alcoholic steatohepati-
tis. Sixty-three (35%) patients had HCC. Fourteen (22%) of these 
were diagnosed incidentally on explant pathology. Patients 
transplanted with HCC were older, with lower natural MELD and 
higher proportion of HCV and HBV infections, and more often 
had a history of prior abdominal surgery. Forty-three (68%) of 
the 63 patients with HCC were treated with at least one bridging 
therapy prior to transplantation, and all patients were within 
Milan criteria (and none were downstaged). Eighteen (42%) of 
these patients underwent TACE initially and 25 (58%) underwent 
ablation. Eleven patients underwent a second bridging proce-
dure – 10 TACE and 1 laparoscopic microwave ablation.
Patient and tumor characteristics are compared between 
bridging therapy groups in Table 2. Most patients had magnetic 
resonance imaging (MRI) at baseline prior to bridging therapy. 
Patients who underwent TACE had more and larger tumors. 
After bridging therapy, 88% of patients had follow-up imaging 
prior to transplantation with MRI or CT. Twenty (80%) patients 
who underwent ablation and 9 (60%) patients who underwent 
TACE had complete response to locoregional therapy based on 
mRECIST imaging criteria, which defines complete response as 
“Disappearance of any intratumoral arterial enhancement in all 
target lesions” (1).
The mean number of days between initial bridging therapy 
and transplantation was 242 (212  days for TACE patients and 
249 days for ablation patients). Explant pathology characteristics 
are detailed in Table 2. Viable tumor was identified in explant 
pathology in 32 patients (74%), including 11 (61%) patients who 
underwent TACE and 21 (84%) patients who underwent ablation. 
For the 21 patients who underwent ablation and had viable tumor 
on explant pathology, 16 (76.2%) had viable tumor in the ablated 
nodule(s) and 5 (23.8%) had viable tumor in both the ablated 
nodule(s) and in one or more separate nodule(s).
Median follow-up was 30  months for the entire cohort 
(33  months for patients alive at last follow-up and 16  months 
for patients who have died). There was no significant differ-
ence in overall survival between patients with and without 
HCC (p = 0.263, Figure 1). Survival was equivalent in patients 
who underwent TACE versus those who underwent ablation 
(p = 0.575, Figure 2). The presence or absence of viable tumor 
was not associated with overall survival in the HCC cohort 
(Figure 3); there was one patient who experienced a recurrence 
during the study period. No other differences in outcomes were 
detected between the viable and non-viable tumor groups.
The patient who experienced recurrence was a 50-year-old 
male with history of abdominal gunshot wound and cirrhosis 
secondary to HCV and HCC. He was diagnosed with two HCC 
TaBle 1 | Descriptive characteristics of entire cohort, hcc group, and non-hcc group.
entire cohort 
(n = 178)
hcc 
(n = 63)
non-hcc 
(n = 115)
hcc,  
bridged 
(n = 43)
hcc,  
non-bridged 
(n = 20)
Tace 
(n = 18)
ablation 
(n = 25)
Liver transplant only 169 (94.9%) 59 (93.7) 110 (95.7%) p = 0.560 42 (97.7%) 17 (85.0%) p = 0.055 18 (100.0%) 24 (96.0%) p = 0.541
Gender male 123 (69.1%) 43 (68.1%) 80 (69.6%) p = 0.856 31 (72.1%) 12 (60.0%) p = 0.337 13 (72.2%) 18 (72.0%) p = 0.888
Age at transplant (mean) 53.14 56.33 51.39 p = 0.001 56.42 56.15 p = 0.903 57.8 55.44 p = 0.466
Age at transplant (median) 55 57 53 p = 0.002 57 56 p = 0.830 56.5 58 p = 0.458
Calculated MELD at 
transplant (mean)
21.87 16.73 24.69 p = 0.000 13.83 22.98 p = 0.000 13.2 14.72 p = 0.820
Pre-transplant AFP 20.09 40.84 7.55 p = 0.020 55.59 8.24 p = 0.225 39.99 67.29 p = 0.607
BMI (mean) 29.8 30 29.75 p = 0.795 29.8 30.44 p = 0.677 29.6 29.93 p = 0.864
Etiology of cirrhosis
Hepatitis C virus 73 (41%) 42 (66.7%) 31 (27%) p = 0.000 28 (65.1%) 14 (70.0%) p = 0.702 10 (55.6%) 18 (72.0%) p = 0.001
Hepatitis B virus 7 (3.9%) 6 (9.5%) 1 (0.9%) p = 0.005 5 (11.6%) 1 (5.0%) p = 0.404 2 (11.1%) 3 (12.0%) p = 0.012
Alcoholic 38 (21.3%) 11 (17.5%) 27 (23.5%) p = 0.349 6 (14.0%) 5 (25.0%) p = 0.282 3 (16.7%) 3 (12.0%) p = 0.371
Non-alcoholic 
steatohepatitis
24 (13.5%) 7 (11.1%) 17 (14.8%) p = 0.493 4 (9.3%) 3 (15.0%) p = 0.503 3 (16.7%) 1 (4.0%) p = 0.318
Alpha-1 antitrypsin 
deficiency
5 (2.8%) 2 (3.2%) 3 (2.6%) p = 0.827 1 (2.3%) 1 (5.0%) p = 0.573 0 (0.0%) 1 (4.0%) p = 0.718
Cryptogenic 13 (7.3%) 1 (1.6%) 12 (10.4%) p = 0.030 0 (0.0%) 1 (5.0%) p = 0.139 0 (0.0%) 0 (0.0%) N/A
Acute liver failure 3 (1.7%) 0 (0%) 3 (2.6%) p = 0. 196 0 (0.0%) 0 (0.0%) N/A 0 (0.0%) 0 (0.0%) N/A
Primary sclerosing 
cholangitis or primary 
biliary cirrhosis
15 (8.4%) 0 (0%) 15 (13%) p = 0.003 0 (0.0%) 0 (0.0%) N/A 0 (0.0%) 0 (0.0%) N/A
Others (n, %) 20 (11.2%) 2 (3.2%) 18 (15.7%) p = 0.012 0 (0.0%) 2 (10.0%) p = 0.035 0 (0.0%) 0 (0.0%) N/A
Medical comorbidities
Diabetes mellitus 45 (25.3%) 15 (23.8%) 30 (26.1%) p = 0.738 11 (25.6) 4 (20.0%) p = 0.628 4 (22.2%) 7 (28.0%) p = 0.910
Prior abdominal surgery 88 (49.4%) 39 (61.9%) 49 (42.6%) p = 0.041 26 (60.5%) 13 (65.0%) N/A 9 (50.0%) 17 (68.0%) p = 0.365
Hypertension 64 (36%) 22 (34.9%) 42 (36.%) p = 0.831 13 (30.2%) 9 (45%) p = 0.252 5 (27.8%) 8 (32.0%) p = 0.642
Coronary artery disease 12 (6.7%) 5 (7.9%) 7 (6.1%) P = 0.638 4 (9.3%) 1 (5.0%) P = 0.556 3 (16.7%) 3 (12.0%) p = 0.686
End-stage renal disease 8 (4.5%) 2 (3.2%) 6 (5.2%) p = 0.529 0 (0.0%) 2 (10.0%) p = 0.035 0 (0.0%) 0 (0.0%) p = 0.263
Atrial fibrillation 4 (2.2%) 0 (0.0%) 4 (3.5%) p = 0.134 0 (0.0%) 0 (0.0%) N/A 0 (0.0%) 0 (0.0%) N/A
COPD 8 (4.5%) 4 (6.3%) 4 (3.5%) p = 0.377 2 (4.7%) 2 (10.0%) p = 0.418 1 (5.6%) 1 (4.0%) p = 0.969
History of arrhythmia (not 
A. Fib.)
2 (1.1%) 1 (1.6%) 1 (0.9%) p = 0.664 1 (2.3%) 0 (0.0%) p = 0.492 0 (0.0%) 1 (4.0%) p = 0.326
Pulmonary hypertension 6 (3.4%) 2 (3.2%) 4 (3.5%) p = 0.915 2 (4.7%) 0 (0.0%) p = 0.327 0 (0.0%) 2 (8.0%) p = 0.310
Esophageal varices 53 (29.8%) 19 (30.2%) 34 (29.6%) p = 0.934 14 (32.6%) 5 (25.0%) p = 0.543 6 (33.3%) 8 (32.0%) p = 0.898
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lesions in segment VI of the liver measuring 1.9  cm ×  2.1  cm 
and 1.5 cm × 1.7 cm. He underwent CT-guided radiofrequency 
ablation of both lesions. Six months later, MRI demonstrated 
a lesion in the left hepatic lobe concerning for HCC and the 
patient underwent left hepatic artery TACE. He did not undergo 
follow-up imaging, and 1 month later, he underwent liver trans-
plantation. He had an uneventful postoperative course. One year 
after transplantation, he presented with elevated liver enzymes 
and underwent blind follow-up liver biopsy, which demon-
strated recurrent HCC. He subsequently underwent MRI, which 
demonstrated multifocal tumor in the liver most consistent with 
HCC, osseous lesions concerning for metastases, and extensive 
upper abdominal and retroperitoneal lymphadenopathy. The 
patient and his family opted for hospice care, and he passed away 
prior to his next follow-up appointment.
DiscUssiOn
Rates of viable tumor in the hepatic explant were high in this 
series after bridging therapy with either TACE or ablation. The 
TaBle 2 | imaging and explant characteristics of patients with hepatocellular carcinoma.
all patients with  
hcc (n = 63)
Tace (n = 18) ablation
imaging prior to bridging therapy
Imaging type MRI 37 (86.0%) 15 (83.3%) 21 (84.0%) p = 0.823
CT 4 (9.3%) 2 (11.1%) 2 (8.0%)
Number tumors median 1.5 1 1 p = 0.014
Largest tumor dimension median (cm) 2.7 2.9 2.3 p = 0.149
imaging after bridging therapy
Imaging type MRI 37 (86.0%) 13 (76.5%) 23 (95.8%) p = 0.134
CT 1 (2.3%) 1 (5.9%) 0 (0.0%)
Post-bridge imaging with HCC Yes 9 (23.7%) 6 (40.0%) 3 (13.0%) p = 0.104
No 29 (67.4%) 9 (60.0%) 20 (87.0%)
explant – patients grouped on first bridging procedure
Viable tumor on explant Yes 50 (79.4%) 11 (61.1%) 21 (84.0%) p = 0.069
No 13 (20.6%) 7 (38.9%) 4 (16.0%)
Number of tumors on explant pathology 0 3 (4.8%) 1 (5.6%) 1 (4.0%) p = 0.642
1 32 (50.8%) 6 (33.3%) 15 (60.0%)
2 13 (20.6%) 6 (33.3%) 5 (40.0%)
3 13 (20.6%) 4 (22.2%) 3 (12.0%)
4 2 (3.2%) 1 (5.6%) 1 (4.0%)
Explant tumor necrosis Yes 39 (62.9%) 12 (66.7%) 20 (80.0%) p = 0.482
No 23 (37.1%) 6 (33.3%) 5 (20.0%)
Explant tumor necrosis, mean (SD) 34.39% 41.20% 47.00% p = 0.787
Explant pathology T-stage TO 3 (4.8%) 2 (11.1%) 1 (4.0%) p = 0.198
T1 27 (42.9%) 4 (22.2%) 13 (52.0%)
T2 23 (36.5%) 8 (44.4%) 6 (24.0%)
T3a 2 (3.2%) 0 (0.00%) 2 (8.0%)
None 8 (12.7%) 4 (22.2%) 3 (12.0%)
Tumor grade 1 12 (24.5%) 2 (20.0%) 1 (4.8%) p = 0.346
2 26 (53.1%) 6 (60.0%) 13 (61.9%)
3 9 (18.4%) 2 (20.0%) 5 (23.8%)
Explant largest tumor diameter in cm, mean (SD) 2.8 2.4 3.8 p = 0.141
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presence of viable tumor in the hepatic explant was not associ-
ated with worse outcome, although our numbers may be under-
powered to detect a difference. Agopian et al. recently reported 
a large series of 501 patients who underwent locoregional 
therapies prior to liver transplantation at a single high-volume 
institution and concluded that 126 patients (25%) had complete 
tumor necrosis. Contrary to our results, they found that complete 
tumor necrosis was associated with superior outcomes. Overall 
survival was not reported in this study. Transplant was done 
for 13% of patients originally outside of Milan criteria in this 
series, and the overall recurrence of HCC was 15.0% in patients 
without complete pathologic response and 2.4% in patients with 
complete pathologic response (15). While the rate of recurrence 
in our study was lower, patient selection is the likely explanation 
as all patients transplanted had HCC within Milan criteria (and 
none were downstaged).
TACE and ablation are common bridging therapies for HCC 
prior to transplantation (15). Reported rates of complete tumor 
necrosis, or complete pathologic response, vary based on treat-
ment modality with response rates between 0 (12) and 57% 
(13) reported for TACE and 8.3 (12) and 74% (14) reported for 
radiofrequency ablation. Generally, patients who achieve trans-
plant after these bridging therapies have excellent outcomes with 
good overall and recurrence-free survival, and these therapies are 
well tolerated without high risk of morbidity (16, 17). Guidelines 
recommend that patients with HCC be considered for bridging 
therapy (10) if they are expected to wait more than 6 months for 
transplantation in order to reduce dropouts from the waitlist 
secondary to tumor progression (11).
This is consistent with prior studies. Marin et al. evaluated 28 
patients with 38 nodules who underwent TACE, selective internal 
radiation therapy (SIRT), and chemical or radiofrequency abla-
tion and noted that 42% of patients had post-bridging imaging 
concerning for HCC and that there was viable tumor in 35 (90%) 
of the 39 treated nodules on explant pathology (12). Lu et  al. 
looked at 47 HCC nodules in 24 patients treated with single or 
double RFA prior to liver transplantation and concluded that 35 
(74%) of the tumors were successfully treated. They determined 
that small lesions and non-perivascular lesions were more likely 
to be successfully treated with this modality and concluded that 
RFA is an effective treatment for small (<3 cm) HCC (14). Wong 
et al. evaluated patients who had undergone TACE, percutaneous 
FigUre 1 | Kaplan–Meier survival curves are shown for patients transplanted with and without hcc.
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FigUre 2 | Kaplan–Meier survival curves are shown for patients bridged with Tace and those bridged with ablation.
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ethanol injection (PEI), and radiofrequency ablation (RFA) and 
determined that of 44 treated nodules, 29 (66%) had a least 75% 
necrosis (18).
Limitations of this study include retrospective design, small 
sample size, and median follow-up slightly <3  years. As men-
tioned, this may mean that the analysis lacked power to detect an 
influence of tumor viability on outcome. Additionally, due to the 
small size of our cohort, we were not able to detect differences in 
other outcomes, including the quality of life. Since the number 
of recurrence cases of HCC is very low, we conclude that trans-
plant after bridging therapy for patients within Milan criteria 
does not require serial bridging to achieve complete pathologic 
tumor response. The presence of complete response by imaging 
is adequate to allow close observation with serial imaging prior 
to transplant.
In conclusion, we determined that although complete patho-
logic response to bridging therapy is not common, this does not 
have an impact on transplantation outcomes. Alternate methods 
FigUre 3 | Kaplan–Meier survival curves are shown for patients with viable tumor on explant pathology and without viable tumor on explant 
pathology after bridging therapy.
may be required to determine if tumor cells that appear viable 
on pathologic analysis are actually alive. Further studies in this 
area could include assessing whether bridged cells are less likely 
to grow in culture or in xenografts in comparison to non-bridged 
(incidental) tumors.
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